This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acquisition Of Epocrates, Inc. By Athenahealth, Inc. May Not Be In Epocrates, Inc. Shareholders' Best Interests

SAN DIEGO and SAN MATEO, Calif., Jan. 7, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Epocrates, Inc. (NASDAQGS: EPOC) by athenahealth, Inc. (NASDAQGS: ATHN).  Epocrates develops applications and interactive services on mobile devices to assist healthcare professionals and pharmaceutical companies.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

On January 7, 2013, athenahealth announced that it had entered into a definitive merger agreement to acquire Epocrates for $11.75 per share.  The transaction has been approved by the board of directors of both companies and is expected to close in the second quarter of 2013.

The Board of Directors' Actions May Prevent Epocrates Shareholders from Receiving the Maximum Value for Their Stock

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Epocrates is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in light of the proposed acquisition.  The $11.75 per share offer price is significantly below the $15 target price set by an analyst at Raymond James Financial. Additionally, the company's stock has traded above the offer price on numerous occasions throughout the last year, with an average trading price of $12.13 since its February 2011 IPO.

Further, each of the directors and certain executive officers of Epocrates entered into voting agreements with athenahealth, pursuant to which they have agreed to vote their shares of Epocrates common stock in favor of the merger with athenahealth and against any acquisition proposal that would interfere with the transaction. Given, these facts, the firm is examining the board of directors' decision to sell Epocrates for $11.75 per share is fair to shareholders or in their own interests.

Epocrates shareholders have the option to file a class action lawsuit against the company to secure the best possible price for shareholders and the disclosure of material information so shareholders can vote on the transaction in an informed manner. Epocrates shareholders interested in information about their rights and potential remedies can contact Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/epocrates-inc/

Attorney Advertising.Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs